from the last presentation  Q1 2018: Results of US clinical...

First 19 Last

Share
Profile

Follow
GCInvestor

2,499 Posts.

207

08/01/18

14:31

Post #: 30128798
Share

Originally posted by TerribleTadpole ↑

Correct. There's a lengthy waiting list of articles waiting for publication in the most respected journals: waiting for peers to be available to conduct the review, then waiting while the peers conduct the review, then waiting in the queue for publication. Really big news can often be summarised earlier in "letters".

In my view, this constraint — "The final results of the study will not be available to Neurotech or the public until the investigation has been published" (italics and underscore are mine) — raises questions over the timing of the FDA application:

1) Can the FDA application be submitted without the trial results? Surely not... otherwise why are we conducting the trial?

2) Can the trial results be submitted directly to the FDA independently by the operators without disclosure to Neurotech? Again, surely not because until the work is reviewed it has no credibility.

I suspect that this is why the market has offloaded NTI... investors have realised they have a wait of up to 6 months before further action is likely. They'll be looking for opportunities in the interim.

Expand

from the last presentation

 Q1 2018: Results of US clinical trial
 Q1 2018: US FDA submission
 Q2 2018: Publication of US trial results in peerreviewed publications
 2018: US FDA determination

seems odd .. will email for some clarification

NTI Price at posting: 22.0¢ Sentiment: Hold Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Chaos reigns markets – so let's take stock of where we're at ahead of December

There are more pages in this discussion • 22 more messages in this thread...

First 19 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 7.0¢		Change 0.001(1.45%)		Mkt cap ! $64.55M

Open	High	Low	Value	Volume
7.1¢	7.1¢	7.0¢	$16.67K	237.0K

Buyers (Bids)

No.	Vol.	Price($)
3	75250	6.9¢

Sellers (Offers)

Price($)	Vol.	No.
7.0¢	23082	1

View Market Depth

No.	Vol.	Price($)
4	589299	0.070
1	36231	0.069
5	240000	0.068
2	255000	0.067
3	262000	0.066

Price($)	Vol.	No.
0.072	100000	1
0.074	40000	1
0.075	738582	2
0.076	90000	1
0.077	190000	3

Last trade - 14.13pm 28/11/2024 (20 minute delay)

NTI (ASX) Chart

from the last presentation  Q1 2018: Results of US clinical...

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Chaos reigns markets – so let's take stock of where we're at ahead of December

Buyers (Bids)

Sellers (Offers)